GSK484 hydrochloride |
| Catalog No.GC19184 |
GSK484 is a selective PAD4 inhibitor with an IC50 of 50 nM without calcium.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1652591-81-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
GSK484 is a selective PAD4 inhibitor, has been used as an anti-ischemic compound and exerts inhibitory activity against PAD4. In the absence of calcium the IC50 value is 50 nM[1-3].
GSK484(25 nM; 1 h before irradiation) facilitated Triple-negative breast cancer (TNBC) cell apoptosis[4]. GSK484(100 nM; 15min) treatment promoted the radiosensitivity of CRC cells and induced cell death by promoting DNA double-strand breaks[5].
GSK484(4 mg/kg; i.p;40days) significantly inhibited tumor size, tumor weight and tumor volume in mice following irradiation in Nasopharyngeal carcinoma (NPC) mice model[6]. GSK484(4 mg/kg; i.p;3days) inhibits PAD4 to reduce distal lung injury by reducing neutrophil infiltration, neutrophil extracellular trap formation, apoptosis, and inflammatory cytokine secretion in mice ischemia reperfusion (IR) model[7].
References:
[1]. Perdomo J, Leung HHL, et,al. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun. 2019 Mar 21;10(1):1322. doi: 10.1038/s41467-019-09160-7. PMID: 30899022; PMCID: PMC6428879.
[2]. Perdomo J, Leung HHL, et,al. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun. 2019 Mar 21;10(1):1322. doi: 10.1038/s41467-019-09160-7. PMID: 30899022; PMCID: PMC6428879.
[3]. Du M, Yang W, et,al. Inhibition of peptidyl arginine deiminase-4 protects against myocardial infarction induced cardiac dysfunction. Int Immunopharmacol. 2020 Jan;78:106055. doi: 10.1016/j.intimp.2019.106055. Epub 2019 Dec 6. PMID: 31816575.
[4]. Wei L, Wang X, et,al. The PAD4 inhibitor GSK484 enhances the radiosensitivity of triple-negative breast cancer. Hum Exp Toxicol. 2021 Jul;40(7):1074-1083. doi: 10.1177/0960327120979028. Epub 2020 Dec 23. Erratum in: Hum Exp Toxicol. 2021 Nov;40(11):2022. PMID: 33355008.
[5]. Wang B, Su X, et,al. GSK484, an inhibitor of peptidyl arginine deiminase 4, increases the radiosensitivity of colorectal cancer and inhibits neutrophil extracellular traps. J Gene Med. 2023 Sep;25(9):e3530. doi: 10.1002/jgm.3530. Epub 2023 May 19. PMID: 37203323.
[6]. Chen H, Luo M, et,al. Inhibition of PAD4 enhances radiosensitivity and inhibits aggressive phenotypes of nasopharyngeal carcinoma cells. Cell Mol Biol Lett. 2021 Mar 16;26(1):9. doi: 10.1186/s11658-021-00251-2. Erratum in: Cell Mol Biol Lett. 2021 Dec 30;26(1):55. Erratum in: Cell Mol Biol Lett. 2023 Apr 4;28(1):29. PMID: 33726680; PMCID: PMC7962337.
[7]. Du M, Yang L, et,al. Inhibition of Peptidyl Arginine Deiminase-4 Prevents Renal Ischemia-Reperfusion-Induced Remote Lung Injury. Mediators Inflamm. 2020 Dec 29;2020:1724206. doi: 10.1155/2020/1724206. PMID: 33456369; PMCID: PMC7787741.
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *